MAIA Biotechnology, Inc.

MAIAReported to SECin USCIK 0001878313Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 13. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 13
Form 4 lines at MAIA Biotechnology, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Vitoc VladChief Executive OfficerOpen-market buy$100,01073,000 sharesSep 15, 2026Vitoc VladChief Executive Officer$100,010Buy · Sep 15Open-market buy73,000Sep 15, 2026
Guerrero Ramiro—Open-market buy$49,51637,595 sharesSep 14, 2026Guerrero Ramiro$49,516Buy · Sep 14Open-market buy37,595Sep 14, 2026
Guerrero Ramiro—Open-market buy$62,93746,620 sharesSep 1, 2026Guerrero Ramiro$62,937Buy · Sep 1Open-market buy46,620Sep 1, 2026
Guerrero Ramiro—Open-market buy$108,75278,239 sharesSep 1, 2026Guerrero Ramiro$108,752Buy · Sep 1Open-market buy78,239Sep 1, 2026
Guerrero Ramiro—Open-market buy$12,4148,931 sharesSep 1, 2026Guerrero Ramiro$12,414Buy · Sep 1Open-market buy8,931Sep 1, 2026